CELLIX BIO PHARMA INITIATES ACQUISITION OF AVACA PHARMA: FORMULATION DEVELOPMENT CROPosted Apr 09, 2020
Cellix Bio Pharma initiates the acquisition of Avaca Pharma, a formulation development CRO. Avaca Pharma services include discovery, formulation development, pre-formulation, regulatory support, and product development activities.
The acquisition of Avaca Pharma provides Cellix Bio Pharma with world-class expertise in NME/NCE discovery R&D services and a unique and extensive set of high-content formulation. Combined with Cellix Bio’s established small molecule discovery and development capabilities, this expansion uniquely position Cellix Bio Pharma as a leading provider of integrated R&D services across both large and small molecule platforms and provides a base for further expansion.
With a shared vision of an innovative approach to execution, exceptional customer service, and focus on providing value, Cellix Bio Pharma is delighted to offer expanded leading-edge service solutions to our clients.